Cover Image

Temporal trends of wild-type transthyretin amyloid cardiomyopathy in the transthyretin amyloidosis outcomes survey

Background - Transthyretin amyloid cardiomyopathy results from the accumulation of wild-type (ATTRwt) or variant (ATTRv) transthyretin amyloid fibrils in the myocardium. THAOS (Transthyretin Amyloidosis Outcomes Survey) is a global, longitudinal, observational survey of patients with ATTRv and ATTRw...

Full description

Saved in:
Bibliographic Details
Main Authors: Nativi Nicolau, Jose N. (Author) , Siu, Alfonso (Author) , Dispenzieri, Angela (Author) , Maurer, Mathew S. (Author) , Rapezzi, Claudio (Author) , Kristen, Arnt (Author) , Garcia-Pavia, Pablo (Author) , LoRusso, Samantha (Author) , Waddington-Cruz, Márcia (Author) , Lairez, Olivier (Author) , Witteles, Ronald (Author) , Chapman, Doug (Author) , Amass, Leslie (Author) , Grogan, Martha (Author) , Barroso, Fabio Adrian (Author) , Van Cleemput, Johan (Author) , Fine, Nowell (Author) , Schmidt, Hartmut (Author) , Gess, Burkhard (Author) , Moelgaard, Henning (Author) , Planté-Bordeneuve, Violaine (Author) , Adams, David (Author) , Inamo, Jocelyn (Author) , Vita, Giuseppe (Author) , Cirami, Calogero Lino (Author) , Luigetti, Marco (Author) , Emdin, Michele (Author) , Sekijima, Yoshiki (Author) , Yamashita, Taro (Author) , Jeon, Eun-Seok (Author) , Gonzalez Duarte Briseno, Maria Alejandra (Author) , Nienhuis, Hans (Author) , Azevedo, Olga (Author) , Campistol Plana, Josep Maria (Author) , Moreno, Juan Gonzalez (Author) , Costello, Jose Gonzalez (Author) , Wixner, Jonas (Author) , Parman, Yesim (Author) , Shah, Sanjiv (Author) , Quan, Dianna (Author) , Marburger, Tessa (Author) , Polydefkis, Michael (Author) , Gottlieb, Stephen (Author) , Ralph, Jeffrey (Author) , Sarswat, Nitasha (Author) , Luo, Jin (Author) , Murali, Srinivas (Author) , Cotts, William (Author) , Drachman, Brian (Author) , Steidley, David (Author) , Hummel, Scott (Author) , Slosky, David (Author) , Ventura, Hector (Author) , Jacoby, Daniel (Author) , Hoffman, James (Author) , Tauras, James (Author) , Zivkovic, Sasa (Author) , Tallaj, Jose (Author) , Lenihan, Daniel (Author) , Mueller, Christopher (Author)
Format: Article (Journal)
Language:English
Published: August 25, 2021
In: JACC: CardioOncology
Year: 2021, Volume: 3, Issue: 4, Pages: 537-546
ISSN:2666-0873
DOI:10.1016/j.jaccao.2021.08.009
Online Access:Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1016/j.jaccao.2021.08.009
Verlag, lizenzpflichtig, Volltext: https://www.sciencedirect.com/science/article/pii/S2666087321002052
Get full text
Author Notes:Jose Nativi-Nicolau, MD, Alfonso Siu, MD, Angela Dispenzieri, MD, Mathew S. Maurer, MD, Claudio Rapezzi, MD, Arnt V. Kristen, MD, Pablo Garcia-Pavia, MD, Samantha LoRusso, MD, Márcia Waddington-Cruz, MD, PHD, Olivier Lairez, MD, PHD, Ronald Witteles, MD, Doug Chapman, MS, Leslie Amass, PHD, Martha Grogan, MD, on behalf of the THAOS Investigators
Description
Summary:Background - Transthyretin amyloid cardiomyopathy results from the accumulation of wild-type (ATTRwt) or variant (ATTRv) transthyretin amyloid fibrils in the myocardium. THAOS (Transthyretin Amyloidosis Outcomes Survey) is a global, longitudinal, observational survey of patients with ATTRv and ATTRwt amyloidosis and asymptomatic patients with transthyretin mutations. - Objectives - This study explored temporal trends in ATTRwt amyloidosis diagnoses using data from THAOS. - Methods - Using THAOS data from December 2007 to January 2020, the following comparisons were made according to year: ATTRwt amyloidosis diagnoses in the United States versus rest of the world, ATTRwt versus ATTRv amyloidosis with cardiac-associated mutations diagnoses, and ATTRwt amyloidosis diagnoses by tissue biopsy versus bone scintigraphy. - Results - There were 1,069 patients with ATTRwt amyloidosis and 525 with ATTRv amyloidosis with cardiac mutations enrolled in THAOS. The median time from symptom onset to ATTRwt amyloidosis diagnosis did not change over the past 5 years (>60 months from 2015-2019). ATTRwt amyloidosis diagnoses increased from 2 in 2005 to >100 per year from 2016, with a more pronounced increase in the United States compared with the rest of the world. Diagnoses of ATTRwt amyloidosis by tissue biopsy increased yearly and peaked in 2014 before declining, whereas diagnoses by bone scintigraphy increased markedly since 2011. ATTRv amyloidosis with cardiac mutation diagnoses increased from 3 in 2005 to 37 in 2011, then plateaued. The proportion of patients with ATTRwt amyloidosis diagnosed with New York Heart Association functional class III/IV heart failure decreased from 2012 (46.4%) to 2019 (16.0%). - Conclusions - In the past decade, ATTRwt amyloidosis diagnoses increased worldwide. Despite the growing utilization of bone scintigraphy, patients are diagnosed several years after symptom onset. (Transthyretin Amyloidosis Outcomes Survey [THAOS]; NCT00628745)
Item Description:Gesehen am 11.02.2022
Physical Description:Online Resource
ISSN:2666-0873
DOI:10.1016/j.jaccao.2021.08.009

Similar Items